España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

atnahs pharma netherlands bv. - propranolol hidrocloruro - comprimido recubierto con pelÍcula - 40 mg - propranolol hidrocloruro 40 mg - propranolol

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

hersil s.a. laboratorios industriales farmaceuticos - clorhidrato de propranolol; - tableta - por tableta - propranolol

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorio icaro s.a. - propranolol hidrocloruro - cÁpsula dura de liberaciÓn prolongada - 160 mg - propranolol hidrocloruro 160 mg - propranolol

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

empresa laboratorios medsol. ueb solmed planta 1 y planta 2, la habana, cuba. - clorhidrato de propranolol - tableta - 10,0 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

empresa laboratorios medsol. unidad empresarial de base (ueb) solmed, planta 1 y planta 2, la habana, cuba. - clorhidrato de propranolol - tableta - 40,0 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

laboratorio farmacÉutico paill, san salvador, el salvador. - clorhidrato de propranolol - solución para inyección iv - 1 mg/ml

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorio icaro, sa - propranolol hidrocloruro - excipientes: n/a - agentes beta-bloqueantes - agentes beta- bloqueantes no selectivos - propranolol

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tipo 2 - drogas usadas en diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

Unión Europea - español - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.